timothy sykes logo
PACB Stock Draws Traders As Verily, TychoBio AI Deals Land Thumbnail
G Google News

PACB Stock Draws Traders As Verily, TychoBio AI Deals Land

MATT MONACO•UPDATED OCT. 21, 2026, 12:33 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Pacific Biosciences of California Inc. stocks have been trading up by 7.91 percent after bullish coverage on its sequencing technology.

Key Takeaways

  • Multi-year Verily Health deal embeds PacBio HiFi long-read sequencing into Verily’s governed cloud and AI platform to create population-scale, AI-ready clinico-genomic datasets.
  • Pacific Biosciences said the Verily collaboration is expected to expand into complex long-read programs serving research, biopharma, and population genomics customers.
  • A separate TychoBio collaboration plugs PacBio HiFi and Kinnex RNA sequencing into AI drug discovery workflows for more than 10,000 rare-disease samples.
  • Pacific Biosciences of California confirmed TychoBio will generate full-length RNA datasets to train AI models that design and evaluate RNA therapies.
  • PacBio also set the date and webcast details for its Q3 2026 earnings call, without sharing preliminary financial numbers.

Candlestick Chart

Live Update At 12:32:36 EDT: On Wednesday, October 21, 2026 Pacific Biosciences of California Inc. stock [NASDAQ: PACB] is trending up by 7.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PACB has been trading like a biotech rollercoaster. Over the past few weeks, Pacific Biosciences of California swung from a late-September close near $1.71 to an early October spike above $3.40 before selling back down toward the low $2s. That kind of move tells traders this is still a high-volatility, news-driven name.

The latest daily close around $2.11 keeps PACB well off its recent highs, but also well above the late-September base near $1.60–$1.80. Intraday today, PACB has been grinding steadily higher from a $1.97 open, with tight five-minute candles between roughly $2.03 and $2.18. That intraday action points to accumulation rather than pure day-trader chaos.

More Breaking News

Fundamentally, Pacific Biosciences is still a heavy cash-burn story. Quarterly revenue of about $39.0M and annual revenue near $160.0M sit against steep negative margins — EBIT margin around -77% and profit margin near -82%. PACB posted roughly -$44.7M in net income for the latest quarter, with operating cash flow about -$35.6M and free cash flow near -$39.2M. The balance sheet shows strong liquidity, though: a current ratio of 4.9 and cash, cash equivalents, and short-term investments around $236.9M. For traders, that combo — high burn but solid cash — usually means runway is there, but dilution risk always stays on the table.

Why Traders Are Watching PACB’s AI Genomics Pivot

PACB is suddenly at the center of two big themes traders love: AI and genomics. The multi-year strategic collaboration with Verily Health is the headline driver. PacBio is plugging its HiFi long-read sequencing workflows directly into Verily’s governed cloud, multimodal health data, and AI platform. In plain English, Pacific Biosciences is becoming part of the core plumbing for Verily’s large-scale clinico-genomic datasets.

For active traders, that matters because this is not a one-off instrument sale. The way the deal is framed, PACB’s long-read technology will help Verily build AI-ready datasets at population scale for biopharma, academic research, and population genomics programs. Pacific Biosciences has also flagged plans to extend this relationship into more complex long-read programs across research and biopharma. That sounds like a platform partnership where Verily keeps coming back for more sequencing capacity.

The TychoBio deal pushes the story even further into AI. PacBio will provide HiFi and Kinnex long-read RNA sequencing on more than 10,000 samples, all aimed at training AI models that design RNA therapeutics for rare diseases. Pacific Biosciences of California spelled out that TychoBio wants full-length RNA datasets, which is exactly where long-read tech shines.

For PACB traders, 10,000+ samples is real volume, not a tiny pilot. It gives near-term utilization for PacBio systems and helps position the company as a key data provider in AI-driven drug discovery. When a small-cap like PACB secures multi-year, AI-centric collaborations on two fronts — Verily at population scale and TychoBio in rare-disease RNA — the narrative can shift quickly from “struggling hardware seller” to “critical data infrastructure.” That narrative alone can attract momentum-driven trading even before the revenue shows up.

Conclusion

PACB sits at an interesting crossroads for active traders. On one side, the financials show a classic high-growth genomics company still deep in the red. Pacific Biosciences’ negative margins, -$44.7M quarterly loss, and heavy free-cash-flow burn remind everyone this is not a slow-and-steady dividend payer. The valuation metrics, like a price-to-sales near 4.6 on roughly $160.0M in revenue, tell traders they are paying for future growth and execution on these new deals.

On the other side, the story flow around PACB is strong. The Verily collaboration embeds Pacific Biosciences into a major AI health-data platform at population scale. The TychoBio partnership locks in more than 10,000 RNA samples for AI-driven therapy design. Both speak to recurring demand for PacBio long-read sequencing as AI models get hungrier for richer data.

With Q3 2026 earnings on deck via webcast and no early numbers yet, traders will be watching to see if management connects these collaborations to order pipelines or backlog. As Tim Sykes likes to say, “The market rewards preparation, not hope — study the pattern, study the catalyst, and always know your risk.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. For PACB, that means tracking how price reacts around news and earnings, managing downside tightly, and letting the AI-genomics story do the heavy lifting on direction. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”